High Dose Consensus Interferon in Nonresponders to Interferon Alpha-2B and Ribavirin with Chronic Hepatitis C
OBJECTIVES: Approximately 60% of patients with chronic hepatitis C treated with a combination of interferon (IFN) alpha-2b and ribavirin are nonresponders. The purpose of the present study was to evaluate the efficacy of treatment with high dose consensus IFN (CIFN) (15 µg/day) in nonresponders.
Saved in:
Main Authors: | David N Moskovitz, Pooma Manoharan, E Jenny Heathcote |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2003-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/2003/131943 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Early Prediction of Nonresponders to Treatment with Interferon Alpha-2B and Ribavirin in Patients with Chronic Hepatitis C
by: Louis WC Liu, et al.
Published: (2003-01-01) -
Ischemic Colitis During Pegylated Interferon-Alpha and Ribavirin Therapy for Chronic Hepatitis C
by: Yvette Leung, et al.
Published: (2006-01-01) -
Treatment of Chronic Viral Hepatitis with Alpha-Interferon: A Consensus Conference Report
by: The CASL Hepatitis Consensus Group
Published: (1994-01-01) -
Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
by: R. Rodríguez-Lojo, et al.
Published: (2010-01-01) -
Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
by: Eric M Yoshida, et al.
Published: (2009-01-01)